62995-79-3Relevant articles and documents
Scalable 9-Step Synthesis of the Splicing Modulator NVS-SM2
Abou-Hamdan, Hussein,Désaubry, Laurent
, p. 2954 - 2958 (2018/03/09)
NVS-SM2, the first activator of pre-mRNA splicing, displays remarkable pharmacological in vivo activities in models of spinal muscular atrophy. Herein we describe an improved approach to the synthesis of this compound, which features a convenient introduction of sterically encumbered amine moiety onto a fluoropyridazine intermediate.
Design, synthesis and biological evaluation of small molecule inhibitors of CD4-gp120 binding based on virtual screening
Lalonde, Judith M.,Elban, Mark A.,Courter, Joel R.,Sugawara, Akihiro,Soeta, Takahiro,Madani, Navid,Princiotto, Amy M.,Kwon, Young Do,Kwong, Peter D.,Sch?n, Arne,Freire, Ernesto,Sodroski, Joseph,Smith III, Amos B.
supporting information; experimental part, p. 91 - 101 (2011/02/28)
The low-molecular-weight compound JRC-II-191 inhibits infection of HIV-1 by blocking the binding of the HIV-1 envelope glycoprotein gp120 to the CD4 receptor and is therefore an important lead in the development of a potent viral entry inhibitor. Reported here is the use of two orthogonal screening methods, gold docking and ROCS shape-based similarity searching, to identify amine-building blocks that, when conjugated to the core scaffold, yield novel analogs that maintain similar affinity for gp120. Use of this computational approach to expand SAR produced analogs of equal inhibitory activity but with diverse capacity to enhance viral infection. The novel analogs provide additional lead scaffolds for the development of HIV-1 entry inhibitors that employ protein-ligand interactions in the vestibule of gp120 Phe 43 cavity.
In the Search for New Anticancer Drugs. 9. Synthesis and Anticancer Activity of Spin-Labeled Analogues of N,N:N',N':N'',N''-Tri-1,2-ethanediylphosphoric Triamide and N,N:N',N':N'',N''-Tri-1,2-ethanediylphosphorothioic Triamide
Sosnovsky, George,Paul, Buddha D.
, p. 782 - 788 (2007/10/02)
A number of N,N:N',N':N'',N''-tri-1,2-ethanediylphosphoric triamide (TEPA) and N,N:N',N':N'',N''-tri-1,2-ethanediylphosphorothioic triamide (thio-TEPA) derivatives containing either two aziridine moieties (1a) or two (2-chloroethyl)amino functions (1b) and either a 2,2,6,6-tetramethylpiperidine, 1-oxy-2,2,6,6-tetramethylpiperidine or 1-hydroxy-2,2,6,6-tetramethylpiperidine component were synthesized and tested against lymphocytic leukemia P388 in mice.In a structure-activity comparison it was found that at optimum dose all compounds containing the nitroxyl radical were more active than the corresponding hydroxylamine derivatives.The open-chain compounds (1b) were less active than the corresponding aziridine ring compounds (1a).The replacement of the X = bridge in 1a with the X = N(CH3) group resulted in lowering of the anticancer activity.
